Veeva Systems Inc. $VEEV Shares Bought by Blair William & Co. IL

Blair William & Co. IL grew its holdings in Veeva Systems Inc. (NYSE:VEEV) by 0.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,289,252 shares of the technology company’s stock after acquiring an additional 4,290 shares during the period. Veeva Systems comprises approximately 1.0% of Blair William & Co. IL’s holdings, making the stock its 16th biggest holding. Blair William & Co. IL owned about 0.79% of Veeva Systems worth $384,081,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Linden Thomas Advisory Services LLC grew its stake in Veeva Systems by 0.3% in the third quarter. Linden Thomas Advisory Services LLC now owns 12,444 shares of the technology company’s stock worth $3,707,000 after purchasing an additional 35 shares in the last quarter. Sigma Planning Corp raised its stake in Veeva Systems by 1.2% during the second quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock valued at $958,000 after buying an additional 39 shares in the last quarter. Personal CFO Solutions LLC lifted its holdings in Veeva Systems by 3.5% during the 3rd quarter. Personal CFO Solutions LLC now owns 1,163 shares of the technology company’s stock worth $346,000 after buying an additional 39 shares during the last quarter. AFT Forsyth & Company Inc. lifted its holdings in Veeva Systems by 4.2% during the 3rd quarter. AFT Forsyth & Company Inc. now owns 984 shares of the technology company’s stock worth $293,000 after buying an additional 40 shares during the last quarter. Finally, Private Trust Co. NA grew its position in shares of Veeva Systems by 17.1% in the 3rd quarter. Private Trust Co. NA now owns 281 shares of the technology company’s stock worth $84,000 after acquiring an additional 41 shares in the last quarter. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VEEV. Wells Fargo & Company cut their target price on shares of Veeva Systems from $333.00 to $317.00 and set an “overweight” rating on the stock in a report on Thursday. Weiss Ratings cut Veeva Systems from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 12th. Stifel Nicolaus raised their price target on Veeva Systems from $212.00 to $245.00 and gave the stock a “buy” rating in a report on Thursday. JPMorgan Chase & Co. dropped their price target on shares of Veeva Systems from $330.00 to $296.00 and set an “overweight” rating on the stock in a research note on Friday, February 20th. Finally, Barclays cut their price target on Veeva Systems from $305.00 to $250.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Seventeen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Veeva Systems presently has a consensus rating of “Moderate Buy” and an average price target of $284.91.

Insider Buying and Selling

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $231.43, for a total value of $231,430.00. Following the completion of the sale, the insider directly owned 23,204 shares of the company’s stock, valued at approximately $5,370,101.72. This represents a 4.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.30% of the company’s stock.

Veeva Systems Price Performance

NYSE VEEV opened at $195.89 on Friday. Veeva Systems Inc. has a 12 month low of $168.13 and a 12 month high of $310.50. The firm has a market capitalization of $32.20 billion, a PE ratio of 36.21, a P/E/G ratio of 1.35 and a beta of 1.09. The company’s 50 day simple moving average is $203.47 and its 200 day simple moving average is $247.42.

Veeva Systems (NYSE:VEEV) last released its earnings results on Wednesday, March 4th. The technology company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Veeva Systems had a return on equity of 14.11% and a net margin of 28.44%.The firm had revenue of $835.95 million during the quarter, compared to the consensus estimate of $810.95 million. During the same period in the prior year, the firm posted $1.74 earnings per share. The firm’s revenue for the quarter was up 16.0% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. Sell-side analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Veeva Systems announced that its board has approved a stock repurchase plan on Monday, January 5th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the technology company to purchase up to 5.5% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

Key Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Q4 beats and raised outlook — Veeva reported revenue of ~$836M (+16% y/y) and non‑GAAP EPS of $2.06, above consensus, and provided FY27 guidance that came in ahead of some estimates, which drove the initial rally. Article Title
• Positive Sentiment: AI and product roadmap cited as growth drivers — Management emphasized “agentic” AI initiatives and CRM expansion (CRM targeted to be ~10% of revenue by 2030), positioning Veeva to capture higher‑value services and offset broader software AI fears. Article Title
• Positive Sentiment: Analyst support and buy ratings remain — Several firms reaffirmed or raised ratings/targets (e.g., Stifel raised target to $245; Truist reaffirmed buy), keeping institutional sentiment constructive despite some cuts. Article Title
• Neutral Sentiment: Earnings call detail available for deeper read — The full Q4 earnings call/transcript provides color on customer uptake, AI timing and margin outlook; useful for investors who want to judge execution risk vs opportunity. Article Title
• Neutral Sentiment: Technical/volume context — Trading volume was a bit below average and the stock remains under its 50‑ and 200‑day moving averages, which can limit near‑term upside until momentum recovers. (See market data summary above.)
• Negative Sentiment: Price‑target cuts and cautious notes — Multiple firms trimmed price targets (Canaccord, Piper Sandler, Needham, RBC, Wells Fargo among others) citing decelerating growth, margin pressure or to reflect model changes—these headlines trimmed upside and likely capped the post‑earnings rally. Article Title
• Negative Sentiment: Ongoing AI disruption debate — Despite Veeva’s positioning, some investors remain worried about how AI will change software economics and competitive dynamics; a few analysts argue AI risk and growth normalization justify a more cautious stance. Article Title

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.